

Ref: EPL/CS/SE/0071/2025**Date:** August 29, 2025

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Update on Re-appointment of Dr. Mukund Gurjar as a Whole-time Director and Appointment of Secretarial Auditor of the Company

We refer to our disclosure dated May 22, 2025 and pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Members of the Company, at their 44th Annual General Meeting ("AGM") of the Members of the Company held on Thursday, August 28, 2025 at 11.00 a.m. (IST) have, *inter-alia*, approved:

- Re-appointment of Dr. Mukund Gurjar (DIN: 00026843) as a Whole-time Director of the Company for a further period of one (1) year commencing from August 28, 2025.
- Appointment of M/s. SVD & Associates, Company Secretaries (UIN: P2013MH031900 and Peer Review No. 6357/2025), as the Secretarial Auditors of the Company, for a term of 5 (Five) consecutive years commencing from FY 2025-26.

The voting results of 44th AGM of the Members of the Company have been submitted with both the Stock Exchanges on August 29, 2025.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Chetan Sharma
Company Secretary & Compliance Officer
Membership Number: F8352

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India
Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060
E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251